肾综合征出血热治疗策略的研究进展

Research progress of therapeutic strategy against hemorrhagic fever with renal syndrome

肾综合征出血热(hemorrhagic fever with renal syndrome, HFRS)是由汉坦病毒感染所致的自然疫源性疾病,发病机制与病毒因素、宿主免疫和遗传因素密切相关。已开发的药物主要针对病毒生命周期、宿主免疫因素或临床对症治疗。新近研发的抑制病毒吸附和复制的新型抗病毒药物、中和抗体、环状肽、多肽化合物、先导抑制剂和小干扰RNA,改善血管功能的达沙替尼、帕唑帕尼、血管生成素1和免疫调节剂等进一步拓宽HFRS治疗策略。本文基于靶向病毒或宿主的药物及对症治疗的研究进展进行综述。

Hemorrhagic fever with renal syndrome(HFRS) is a natural focus disease caused by hantavirus infection, and basic pathogenesis is highly involved in virus factors, host immunity factors and genetic factors.The medicines developed mainly target the viral life cycle, host immunological factors, or clinical symptoms.Recently, new antiviral drugs, neutralizing antibodies, cyclic peptides, polypeptide compounds, lead inhibitors and small interfering RNA inhibited virus adsorption and replication, dasatinib, pazopanib, angiopoietin-1 and immunomodulators improved vascular function have been developed to further broaden HFRS treatment strategies.This paper reviews the research progress of medicines targeting virus or host and symptomatic treatment.